Litigation Details for Farag v. Health Care Service Corporation, d/b/a Blue Cross Blue Shield of Illinois (N.D. Ill. 2017)
✉ Email this page to a colleague
Farag v. Health Care Service Corporation, d/b/a Blue Cross Blue Shield of Illinois (N.D. Ill. 2017)
Docket | ⤷ Sign Up | Date Filed | 2017-04-04 |
Court | District Court, N.D. Illinois | Date Terminated | 2017-07-05 |
Cause | 28:1331 Federal Question | Assigned To | Harry Daniel Leinenweber |
Jury Demand | None | Referred To | |
Patents | 6,294,197 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Farag v. Health Care Service Corporation, d/b/a Blue Cross Blue Shield of Illinois
Details for Farag v. Health Care Service Corporation, d/b/a Blue Cross Blue Shield of Illinois (N.D. Ill. 2017)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2017-07-05 | 38 | order on motion to dismiss | inventors listed on Novartis’ U.S. Patent No. 6,294,197 (“the ’197 patent”), which covers a tablet form of…toward a patent issued to Hoffman- LaRoche, Inc., U.S. Patent No. 5,696,116 (“the ’116 patent”), claiming…validity or enforceability of the ’197 patent – or any patent Novartis holds on Diovan. …1965) (“[T]he enforcement of a patent procured by fraud on the Patent Office may be violative of § 2 …plaintiff to strip a patent holder of its exemption from the antitrust laws if its patent was procured | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |